Thank you for helping ELSO disseminate information by entering your experience in the ELSO Registry as soon as ECMO is implanted - before the run is complete. Instructions for entering data in the Registry and COVID-19 addendum can be found on the Data Definitions page.



We recognize you cannot complete and submit the entire ELSO Registry case report form prior to completion of the ECMO run and discharge from the hospital, but we would still like to have the data you know now.



To address concerns about incomplete data we report three nested data sets to accommodate the fact that different patients will be at different stages of care (and thus have more or less incomplete data). Also when considering the data please understand that the data displayed is a real-time data stream and subject to change as more patient information is accrued and as centers update the ELSO Registry Case Report Form and the ELSO COVID-19 addendum.

COVID-19 Cases on ECMO in the ELSO Registry

Total COVID-19 Cases COVID-19
Confirmed Cases
17,716
Total counts of COVID-19 confirmed patients.

COVID-19 ECMO counts by ELSO Chapter

Still on ECMO Still Hospitalized at ELSO Center Total (n)
All ELSO 345 636 17,811
          North America 78 123 11,241
          Europe 130 185 3,533
          Asia Pacific 38 90 576
          Latin America 76 191 1,272
          SWAAC 23 47 1,189
Reports counts of ECMO-supported suspected or confirmed COVID-19 cases by ELSO Chapter

Filters affect the data shown in the tables below:

Year To Date

Region

Patient Age


Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
16,302
COVID-19
In-hospital Mortality
48%

Outcomes

Pre-ECMO Patient Factors

Patient-level summaries of COVID ECMO runs. All categorical variables are given as 'percentage (count)'
Total ARDS Cohort
Number cases 16302 12025
Age(years)
Median(IQR) 47(37,56) 48(38,56)
# observed 16302 12025
BMI, kg/m2
Median(IQR) 32(27,37) 32(28,38)
# observed 15118 11124
Sex
Male 68%(11109) 69%(8348)
Female 32%(5189) 31%(3674)
# observed 16298 12022
Race/Ethnicity
Black 11%(1717) 10%(1211)
White (Non-Hispanic) 44%(7190) 44%(5236)
Asian 9%(1429) 8%(989)
Mid East, N African 4%(704) 5%(578)
Other 3%(466) 3%(344)
Unknown 5%(791) 5%(605)
Multiple 5%(837) 6%(694)
Hispanic 19%(3168) 20%(2368)
# observed 16302 12025
Pre-ECMO Comorbidities
No comorbidity 26%(4227) 24%(2946)
Cancer 2%(312) 2%(214)
Pregnancy 4%(646) 4%(491)
Immunocompromised 5%(833) 5%(612)
Diabetes 23%(3787) 24%(2900)
Pre-existing heart disease 4%(710) 3%(345)
Pre-existing lung disease 4%(655) 4%(479)
Pre-existing renal insuff. 3%(507) 3%(346)
Frailty 1%(147) 1%(84)
Asthma 10%(1639) 10%(1247)
BMI $> 30 \mathrm{kg}/\mathrm{m}^2$ 48%(7876) 51%(6134)
Hypertension 31%(4986) 32%(3822)
# observed 16302 12025
Acute illness
ARDS 78%(12754) 100%(12025)
Acute heart failure 9%(1438) 5%(612)
Myocarditis 2%(405) 1%(66)
Acute kidney injury 26%(4286) 27%(3222)
# observed 16302 12025
Pre-ECMO Cardiac Arrest
Yes 7%(1107) 3%(363)
No 93%(15061) 97%(11558)
# observed 16168 11921
Pre-ECMO Co-Infection
No Co-infection 49%(7972) 46%(5544)
Bacterial pneumonia 44%(7150) 47%(5708)
Co-viral infection 9%(1537) 9%(1081)
Blood stream infection 18%(2912) 19%(2282)
Urinary tract infection 7%(1215) 8%(1010)
# observed 16300 12023

Pre-ECMO Interventions

Support and therapies. All categorical variables are given as 'percentage (count)'
PreECLS PreECLS
Number cases 16302 12025
Noninvasive ventilation
Noninvasive ventilation prior to intubation 75%(12272) 80%(9583)
BiPAP 37%(6079) 41%(4888)
CPAP 12%(2032) 12%(1440)
HFNC 51%(8245) 55%(6588)
# observed 16302 12025
Pre-ECLS intubation (days)
Median(IQR) 2.8(0.7,5.9) 3.2(1.0,6.2)
# observed 13502 10023
Ventilator mode
Conventional 96%(13188) 97%(10085)
# observed 13791 10411
PEEP, cm H2O
Median(IQR) 14.0(10.0,16.0) 14.0(10.0,16.0)
# observed 12232 9393
PIP, cm H2O
Median(IQR) 33.0(29.0,38.0) 34.0(30.0,38.0)
# observed 9783 7443
FiO2
Median(IQR) 1.00(0.95,1.00) 1.00(1.00,1.00)
# observed 12138 9176
PaO2/FiO2
Median(IQR) 70(57,92) 70(57,89)
# observed 11862 8977
PCO2
Median(IQR) 60(49,74) 61(51,75)
# observed 12625 9498
Pre-ECMO Support
Prone positioning 51%(8205) 55%(6630)
# observed 16247 11993
Neuromuscular blockers 66%(10803) 71%(8557)
# observed 16250 11992
Inhaled pulmonary vasodilators 28%(4476) 30%(3632)
# observed 16247 11993
Any vasoactive support 57%(9312) 56%(6689)
# observed 16245 11986
Norepinephrine 51%(8227) 51%(6079)
# observed 16245 11986
Therapies, Immunomodulators
Any therapy 86%(14073) 90%(10793)
Glucocorticoids 77%(12627) 81%(9746)
IVIG 3%(461) 2%(242)
Anti-cytokine 21%(3449) 24%(2831)
Lopinavir/Ritonavir 2%(281) 2%(229)
JAK inhibition 4%(578) 4%(488)
Chloroquine/hydroxychloroquine 6%(1026) 7%(833)
Remdesivir 48%(7787) 51%(6159)
# observed 16302 12025
Support type
Respiratory 92%(14998) 100%(11998)
Cardiac 6%(992) 0%(12)
ECPR 2%(312) 0%(15)
# observed 16302 12025

Patient Status & Complications

Outcomes
Total ARDS Cohort
Last known patient status
Discharged alive to home or acute rehabilitation 27%(4323) 26%(3092)
Discharged alive to long-term acute care or unspecified location 12%(1886) 13%(1512)
Discharged to another hospital 12%(1900) 11%(1323)
Remain in the hospital (discharged from ICU) 0%(6) 0%(3)
Remain in the ICU 0%(29) 0%(21)
In-hospital death 50%(8158) 51%(6074)
Tracheostomy 46%(6756) 50%(5501)
# observed 14791 10915
Select complications
Seizures 1%(126) 1%(88)
# observed 16265 11993
CNS infarction by US/CT/MRI 2%(277) 1%(162)
# observed 16265 11993
CNS hemorrhage by US/CT/MRI 6%(1025) 7%(801)
# observed 16265 11993
Hemolysis 7%(1177) 8%(902)
# observed 16265 11993
Oxygenator failure 21%(3360) 23%(2780)
# observed 16265 11993
Pump failure 2%(332) 2%(263)
# observed 16265 11993
Circuit change 11%(1754) 12%(1400)
# observed 16265 11993
Thrombosis/Clots in circuit component 3%(534) 4%(427)
# observed 16265 11993
Discharge location
Home 32%(2557) 31%(1823)
Transfer to LTAC or Rehab
Transfer to another hospital 23%(1900) 22%(1323)
Other/Unknown 6%(454) 5%(316)
*N/A - Data elements with n<5 are not displayed.